Citation

Schweighardt AE, Juba KM. Ann. Pharmacother. 2014; 48(10): 1362-1365.

Affiliation

St John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA kjuba@sjfc.edu.

Copyright

(Copyright © 2014, Harvey Whitney Books)

DOI

10.1177/1060028014543174

PMID

25164521

Abstract

Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.

Keywords: Social Transition

Language: en